Early laboratory data on the effectiveness of existing vaccines against the Omicron COVID-19 variant is useful, but it is still unclear how effective these will be in treating severely sick patients, a UN health agency panel said on Thursday.
The development follows reassurance from the World Health Organization (WHO) that available vaccines "hold up very well" in protecting people from the worst forms of coronavirus sickness for six months or more, with a "minor, modest reduction" thereafter, particularly among over-65s or those with underlying medical conditions.
"The neutralization data has an underpinning, but it's really the clinical data that are going to be most influential about how to manage an Omicron situation," said Dr Kate O'Brien, Director, Department of Immunization, Vaccines and Biologicals at WHO.
On the issue of herd immunity, Dr O'Brien said that collective immunity remained out of reach, partly because the vaccines in circulation today, for all their efficacy, were "not performing at the level where the concept of herd immunity is likely to be something that can be achieved".
This was at least in part because of the lack of universal vaccine coverage which has seen wealthier countries benefit from immunization campaigns, while poorer nations have suffered a dearth of lifesaving jabs, Dr O'Brien noted.
On so-called "breakout infections" among individuals already vaccinated, it was "not surprising" that these had increased in line with greater vaccination coverage, the WHO official insisted.
"That does not mean the vaccine is not working, it simply means that a greater and greater number of people have actually been vaccinated."
As Omicron spreads, Dr O'Brien highlighted that those most at risk remained the unvaccinated, who represented 80 to 90 per cent of those who have fallen seriously ill from coronavirus.
( With inputs from ANI )
Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor